Evogene Ltd. (TLV: EVGN)
Israel flag Israel · Delayed Price · Currency is ILS · Price in ILA
666.00
+18.20 (2.81%)
Nov 19, 2024, 3:56 PM IDT

Evogene Statistics

Total Valuation

Evogene has a market cap or net worth of ILS 35.00 million. The enterprise value is 22.86 million.

Market Cap 35.00M
Enterprise Value 22.86M

Important Dates

The last earnings date was Sunday, November 17, 2024.

Earnings Date Nov 17, 2024
Ex-Dividend Date n/a

Share Statistics

Evogene has 5.37 million shares outstanding. The number of shares has increased by 21.04% in one year.

Current Share Class n/a
Shares Outstanding 5.37M
Shares Change (YoY) +21.04%
Shares Change (QoQ) +0.57%
Owned by Insiders (%) 1.57%
Owned by Institutions (%) 5.16%
Float 4.97M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio 0.92
PB Ratio 2.88
P/TBV Ratio n/a
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings -0.31
EV / Sales 0.64
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF -0.30

Financial Position

The company has a current ratio of 1.58, with a Debt / Equity ratio of 0.04.

Current Ratio 1.58
Quick Ratio 1.32
Debt / Equity 0.04
Debt / EBITDA n/a
Debt / FCF -0.04
Interest Coverage n/a

Financial Efficiency

Return on equity (ROE) is -82.37% and return on invested capital (ROIC) is -50.33%.

Return on Equity (ROE) -82.37%
Return on Assets (ROA) -28.46%
Return on Capital (ROIC) -50.33%
Revenue Per Employee 250,538
Profits Per Employee -526,769
Employee Count 142
Asset Turnover 0.20
Inventory Turnover 3.37

Taxes

Income Tax n/a
Effective Tax Rate n/a

Stock Price Statistics

The stock price has decreased by -73.78% in the last 52 weeks.

Beta (5Y) n/a
52-Week Price Change -73.78%
50-Day Moving Average 911.52
200-Day Moving Average 1,923.24
Relative Strength Index (RSI) 25.37
Average Volume (20 Days) 111,925

Short Selling Information

Short Interest n/a
Short Previous Month n/a
Short % of Shares Out n/a
Short % of Float n/a
Short Ratio (days to cover) n/a

Income Statement

In the last 12 months, Evogene had revenue of ILS 35.58 million and -74.80 million in losses. Loss per share was -14.89.

Revenue 35.58M
Gross Profit 28.96M
Operating Income -80.86M
Pretax Income -79.19M
Net Income -74.80M
EBITDA -74.07M
EBIT -80.86M
Loss Per Share -14.89
Full Income Statement

Balance Sheet

The company has 78.72 million in cash and 3.05 million in debt, giving a net cash position of 75.67 million or 14.10 per share.

Cash & Cash Equivalents 78.72M
Total Debt 3.05M
Net Cash 75.67M
Net Cash Per Share 14.10
Equity (Book Value) 75.08M
Book Value Per Share 2.27
Working Capital 35.73M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -74.58 million and capital expenditures -1.78 million, giving a free cash flow of -76.36 million.

Operating Cash Flow -74.58M
Capital Expenditures -1.78M
Free Cash Flow -76.36M
FCF Per Share -14.23
Full Cash Flow Statement

Margins

Gross margin is 81.42%, with operating and profit margins of -227.27% and -210.26%.

Gross Margin 81.42%
Operating Margin -227.27%
Pretax Margin -222.59%
Profit Margin -210.26%
EBITDA Margin -208.19%
EBIT Margin -227.27%
FCF Margin -214.64%

Dividends & Yields

Evogene does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -21.04%
Shareholder Yield -21.04%
Earnings Yield n/a
FCF Yield n/a

Stock Splits

The last stock split was on July 28, 2024. It was a reverse split with a ratio of 0.1.

Last Split Date Jul 28, 2024
Split Type Reverse
Split Ratio 0.1

Scores

Evogene has an Altman Z-Score of -9.26. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score -9.26
Piotroski F-Score n/a